Getting the Message Across: A Recent Transporter Structure Shows the Way  by Henry, L. Keith et al.
Neuron 49, 791–796, March 16, 2006 ª2006 Elsevier Inc. DOI 10.1016/j.neuron.2006.03.002MinireviewGetting the Message Across:
A Recent Transporter Structure
Shows the WayL. Keith Henry,1 Louis J. DeFelice,1
and Randy D. Blakely1,*
1Department of Pharmacology and
Center for Molecular Neuroscience
Vanderbilt University School of Medicine
Nashville, Tennessee 37232
Efforts to define the mechanisms governing neuro-
transmitter uptake and drug action have moved into
high gear with the publication of a high-resolution
structureofa leucine transporter fromAquifexaeolicus,
a bacterial member of the SLC6 transporter family.
Solved with the substrate leucine bound, the new
structure corroborates extensive biochemical andmu-
tagenesis studies performed with related mammalian
neurotransmitter transporters and provides exciting
suggestions as to how coupling arises between ions
and substrates to permit efficient neurotransmitter
clearance.
Thousands of riders gain access to city subways every
day by plunking tokens into clanking turnstiles that limit
transit access (for the most part) to paying customers.
At the synapse, membrane transporters are the turn-
stiles. The would-be travelers are neurotransmitters
like GABA, dopamine, norepinephrine, and serotonin
(but also other solutes such as neurotransmitter precur-
sors). The coins of this realm are sodium, chloride, and
potassium ions, profitably engaged in a process the
transporter cognoscenti call ‘‘coupling,’’ or the transfor-
mation of ion gradients into the energy needed to pump
neurotransmitters across membranes, often against
their own concentration gradients. Ion-coupled solute
transfer across membranes is as essential for the less
complex forms of life as it is for neurons. Indeed, such
transporter genes make up significant fractions of mi-
croorganismal genomes, allowing essential nutrients
to be gobbled from the environment, permitting cells
to buffer themselves against osmotic stress via transfer
of organic osmolytes, and permitting the elimination of
toxins arising from hostile organisms or metabolic trash.
In mammalian cells, ion-coupled transporters perform
these same actions, quite often doing so in parallel
with so-called ‘‘facilitated transport’’ systems, trans-
porters that rely solely on solute gradients for transport
across the membrane (similar in many ways to chan-
nels), and ‘‘pumps,’’ membrane proteins that hydolyze
ATP to achieve solute flux.
Although we have known about ion-coupled neuro-
transmitter transport for decades (Iversen and Kravitz,
1966), there is still only a vague understanding of how
coupling is achieved at a molecular level informed by au-
thentic transporter protein structures. The fact is that
one need not understand the particulars of a turnstile’s
mechanical innards to appreciate what they do. Analo-
*Correspondence: randy.blakely@vanderbilt.edugously, what channels do and how they work antici-
pated much of the fine structural data—and so it has
been with neurotransmitter transporters. It is clear that
their chief activity is to clear neurotransmitter after re-
lease, thereby shaping the magnitude and duration of
chemical signaling, limiting neurotransmitter spillover
to neighboring synapses, and recycling neurotransmit-
ter for subsequent rerelease (Iversen, 1971).
Need we know more? Like turnstiles, sometimes neu-
rotransmitter transporters grind to a halt (from muta-
tions), get blocked (e.g., cocaine, antidepressants), or,
with a little forced ratcheting, allow passengers to slip
through without a token (uncoupled substrate move-
ments). Some drugs, particularly the amphetamines,
can send transporters spinning madly in reverse or allow
many travelers to go through with a single token (Kahlig
et al., 2005). Transporters also sometimes leave the
plasma membrane (trafficking) or just refuse to work
even though prompted to do so (inactivation), pro-
cesses that can be impacted by the neurotransmitter it-
self (Ramamoorthy and Blakely, 1999). Finally, the basic
process of ion coupling is central to how these trans-
porters get the job done, and perhaps it is here that
we understand the least. The number or ‘‘stoichiometry’’
of ions required for coupling varies among transporters
and can therefore result in some transporters being ei-
ther ‘‘electrogenic’’ or ‘‘electroneutral,’’ assignations
given on the basis of cumulative charge required for
a single transport ‘‘event.’’ Whether variance in ion-to-
solute ratios is indicative of different transporters having
distinct molecular features for ion binding embedded in
their structure is unknown, but there are even more per-
plexing issues. In addition to the normal substrate/ion-
coupled transport exhibited by many members of the
NSS family, substrate-independent ‘‘leak’’ currents oc-
cur (see Figure 1) as if transporters occasionally decide
to imitate ion channels. Even more perplexing are chan-
nel-like flux states identified for solutes themselves
(Blakely et al., 2005), blurring distinctions so seemingly
well-defined by the use of distinct names like ‘‘trans-
porter’’ and ‘‘channel.’’ It is possible that all three modes
illustrated in Figure 1 exist at the same time in the mem-
brane or are interconverted in response to intra- and ex-
tracellular input. Recently, transporter-interacting pro-
teins have been found to modify flux stoichiometry,
seemingly tampering with the fundamental mechanisms
that support standard transporter definitions (Quick,
2003). Thus, although the fine structure of ion-coupled
transporters is not required to comprehend their func-
tion, to make sense of these functional nuances one
has to gain access to a transporter’s inner workings.
Gouaux and coworkers have recently done just that
by achieving the first high-resolution (1.65 A˚) X-ray
structure of a transporter in the SLC6 (or Na:Solute
Symporter, NSS) family, the leucine transporter (LeuTAa)
from Aquifex aeolicus (Yamashita et al., 2005). Prokary-
otic homologs of mammalian membrane proteins have
proved to be the path of least resistance to obtaining
high-resolution structures, e.g., K channels (Doyle et al.,
1998), Cl/H exchangers (Accardi and Miller, 2004), and
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792Figure 1. Modes of Transport for Neurotransmitter Transporters
Antiparallel structure is represented here and denoted as TM 1–5 and 6–10 as found in the LeuTAa structure. (A) Coupled transport: stoichiometric
coupling of substrate (S) to x number of ions (I) (in this case 3). (B) ‘‘Leak’’ current: an ion current observed in the absence of substrate. (C) Sub-
strate-gated channel: at high substrate concentrations, ion conductance becomes markedly larger than substrate translocation exhibiting chan-
nel-like properties.the proton-coupled, lactose transporter (Abramson
et al., 2003). The advantages of prokaryotic proteins de-
rive from their general lack of posttranslational process-
ing (e.g., N-glycosylation) and the ease of production to
a scale needed for crystallization. The strategy to seek
insights of neuronal transporters from prokaryotic ho-
mologs now seems an obvious path needing little de-
fense; one need only review the accelerated pace of
ion channel research that has followed the structural elu-
cidation of prokaryotic homologs of voltage-gated po-
tassium channels (MacKinnon, 2003) to understand the
driving forces behind the LeuTAa work. One concern,
however, is that the LeuTAa sequence is only w25%
identical with mammalian neurotransmitter transporters,
such as transporters for the brain’s major inhibitory neu-
rotransmitter GABA (GAT-1–3), the cocaine-sensitive
dopamine transporter (DAT), or the antidepressant-sen-
sitive norepinephrine and serotonin transporters (NET
and SERT, respectively). Though only distantly related
to mammalian Na/Cl-coupled neurotransmitter trans-
porters, SLC6-conserved residues and LeuTAa topology
make a strong case that LeuTAa is clearly in the bloodline.
As predicted by initial hydropathy models, the binding
site for substrates is surrounded by twelve transmem-
brane domains (TMs) connected to cytoplasmic N and
C termini (Figure 2). However, not every feature known
to mammalian SLC6 devotees is well represented in
the LeuTAa structure. For example, the extracellular
loop between TMs 3 and 4 is a noticeably smaller domain
in LeuTAa, and the loop that is present lacks sites for
N-glycosylation as well as a critical disulfide linkage.
Although these missing features do not diminish the
relevance of the core structure of LeuTAa to the SLC6
family, it is important to note that regulation of ion/sub-
strate ratios and transport function may be mediated
through features absent in the LeuTAa structure. Evident
in the LeuTAa structure is a previously unrecognized
2-fold symmetry relating TMs 1–5 to TMs 6–10, with
these two domain sets interdigitated and reflected in
the plane of the membrane. In this regard, LeuTAa joins
a growing number of bacterial transporters like NhaA,
EmrE, Amt-1, and others whose crystal structures indi-
cate use of antiparallel architecture, giving rise to
a pseudo or true 2-fold axis of symmetry (Pornillos and
Chang, 2006). Therefore, whereas it is exciting that the
LeuTAa structure has broad resemblances to bona fide
neurotransmitter transporters, more exciting are thefine details that give us clues as to how these nanoma-
chines actually work, how neurotransmitters and drugs
are recognized, and how coupling is achieved. With fur-
ther study, the common organizational theme of antipar-
allel symmetry may provide insight into not only the
necessary structural components used to support neu-
rotransmitter transport, but also clues to mechanisms
used by other ion-driven transporters.
As expected, LeuTAa has an absolute requirement for
Na (as in all SLC6 members) though not Cl (as in some
other SLC6 members). Indeed, leucine and Na ions
were trapped in the solved structure. Actually, two Na
ions were found in the structure, cradled by TMs 1, 3,
6, and 8 and in proximity to substrate, though whether
both Na ions are involved in supporting leucine transport
is unknown. TMs 1 and 6 are two of the most conserved
domains throughout the SLC6 family, consistent with an
evolutionarily constrained contribution to the transport
process. Interestingly, these domains are not simple he-
lical structures spanning the bilayer but are interrupted
halfway through the membrane, just adjacent to the
sites for leucine and Na binding, by extended, nonhelical
structures. TMs 3 and 8 make important, but far more
discrete, contributions to the substrate binding area
due to a striking tilt of the two helices, leaning w50º
off the vertical plane and intersecting TMs 1 and 6 to
bring only a few residues in proximity to substrates. In
turn, TMs 3 and 8 are nestled between V-shaped inter-
sections of TMs 9 and 10 and TMs 4 and 5, respectively.
These features of interhelical packing are quite distinct
from first generation ‘‘circle the wagons’’ models (Ed-
vardsen and Dahl, 1994), which organized TMs next to
one another, circling a central pore, and they are also
very different from the solved structures of the bacterial
glutamate transporter (Yernool et al., 2004) and LacY,
the prokaryotic transporter for lactose (Abramson
et al., 2003).
One feature in common, however, between glutamate
and leucine transporter structures is the postulated role
of two gates at the cytoplasmic and periplasmic sides of
each protomer in the structure. The two-gate hypothesis
for Na-substrate coupling is a version of the much older
alternating access model of coupled transport and has
been proposed for SERT (Lester et al., 1994) and for
NA/K ATPase (Artigas and Gadsby, 2003). A more con-
ventional alternating access model with large confor-
mational changes has been proposed for the LacY
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793Figure 2. LeuTAa 3D Structure
(A) View of barrel helical representation of
LeuTAa as viewed in the plane of the mem-
brane. Transmembrane, extramembrane (EL),
intramembrane (IL) helices, and b strand re-
gions are numbered. L-leucine (yellow), Na
(purple), and Cl (green) are represented as
CPK models. Helical domains outside of the
membrane are represented as coils. (B) View
from extracellular side. (C) View from intra-
cellular side. (Images for Figures 2, 3, and 4
were created from LeuTAa PDB file 2A65 or
modeled hSERT using PyMol [DeLano, 2002].)mechanism (Abramson et al., 2003). In ion channels,
the interface of the protomers typically forms the con-
duction pathway. The LeuTAa structure indicates that
a single gene product is responsible for substrate trans-
port, though monomer complexes may pack together in
a higher-order structure through perimeter helices.
There is evidence for monomer-supported substrate
flux from a fluorescent study of substrate binding to
NET (Schwartz et al., 2003). Nevertheless, there are
strong structural and functional analogies between
transporters and channels that are yet to be fully ex-
plored (Accardi and Miller, 2004; DeFelice, 2004). Evolu-
tion appears to have solved the problem of moving sol-
utes across membranes by multiple strategies. For
transporters, we are just getting started in this game,
as many transporter gene families pepper the genomes
of all organisms and most have yet to be resolved struc-
turally.
Importantly, biochemical evidence from homologous
mammalian transporters elevates our confidence in the
LeuTAa crystal structure. One of the most useful and
widely used methods of probing amino acid environ-
ments in membrane proteins is the substituted cysteine
accessibility method (SCAM). Prior to the current LeuTAa
crystal structure, SCAM analysis of human SERT
(hSERT) predicted that TM 1 formed part of the perme-
ation pathway for 5-HT and suggested that the pathway
becomes occluded at residues in the helix cytoplasmic
to Tyr95 (Henry et al., 2003). In agreement with the
LeuTAa crystal structure, hSERT Gly94, Tyr95, Asp98,
Gly100, and Asn101 (residues homologous to partici-
pants of leucine binding in LeuTAa) were predicted to
lie near the substrate binding pocket (Henry et al.,
2003). SCAM analysis of the GABA transporter GAT-1
TM1 provided similar findings and suggested that TM1
is a conserved element supporting substrate recogni-tion in the SLC6 family (Zhou et al., 2004). As confirmed
in the LeuTAa structure, GAT-1 TM1 was also predicted
to be unwound near the center of the membrane.
But how is differential substrate recognition sup-
ported? What makes LeuTAa substrate recognition dis-
tinct from that of GAT-1 or SERT, permitting the wide va-
riety of substrates transported in the SLC-6 family?
Certainly one can envision remodeling of the LeuTAa hy-
drophobic substrate binding site during evolution to ac-
commodate various neurotransmitters. As mutation
studies stride forth with the LeuTAa blueprint, we may
be able to explain both the specificity and the promiscu-
ity of transporters for their substrates. Returning to the
turnstile analogy, if we truly understand how substrate
recognition is achieved, we should be able to make the
turnstile accept a penny in place of a token. With this in
mind, we initiated a cursory modeling procedure to
map the hSERT residues onto the LeuTAa structure by
overlay of the hSERT sequence directly onto the coordi-
nates of the LeuTAa PDB ID 2A65 per the alignment
reported by Yamashita et al. As a coarse method to
account for the few amino acid substitutions in the
binding site, the resulting PDB file was analyzed (with
help from Drs. Jens Meiler and Eric Dawson, Vanderbilt
Center for Structural Biology) using SCWRL3 (Canu-
tescu et al., 2003) (a simple energy function based on
a backbone-dependent rotamer library and a linear
repulsive steric energy) to alter only the c1 and c1+2 an-
gles of the side chain to minimize steric clashes while
leaving the backbone rigid to assign the most probable
rotomer angles to SERT side chains. Visualization of
a SERT-like remodeled leucine binding pocket allows
for initial comparisons between the hSERT and LeuTAa
binding pockets. The model combined with previous
biochemical and pharmacological analyses of substrate
interaction with TMs 1 and 3 of hSERT (Adkins et al.,
Neuron
794Figure 3. Comparison of Hydrophobic Bind-
ing Pockets from LeuTAa
Crystal Structure and hSERT Model. (A) Hy-
drophobic binding pocket of LeuTAa- trans-
porter side chains (gray) and L-leucine side
chain (yellow) are represented by stick
models surrounded by semitransparent Van
der Waals surface spheres. (Adapted and re-
printed by permission from Macmillan Pub-
lishers Ltd: Nature, Yamashita et al., 2005,
copyright 2005.) (B) Conceptualization of 5-
HT within the modeled hSERT binding site.
hSERT residues here mapped onto LeuTAa
coordinates and probable side chain confor-
mations were determined by SCWRL3 roto-
mer library analysis while maintaining the
LeuTAa backbone. Amino acid changes in
binding pocket are represented as colored
residues: Y95 (red), I172 (green), and G442
(blue).2001; Barker et al., 1998; Henry et al., 2003, 2006) en-
ables us to propose a rough illustration of the binding
pocket and the residues that appear to play a major
role in substrate recognition (Figure 3). Although this pre-
sentation is not meant to be a full computational analysis
of the 5-HT binding pocket in SERT, this first glimpse
suggests the features that may be evident in the 5-HT
binding site where a larger binding space may be af-
forded by the presence of smaller side chains nestling
the substrate binding pocket in SERT and its close rela-
tives. Residues Ile359 and Ser256 in the hydrophobic
binding pocket of LeuTAa become glycines in SERT
and DAT, and these smaller side chains may permit bind-
ing of the bulkier 5-HT and DA structures. Two other do-
mains ascribed to substrate/antagonist recognition,
TMs 11 and 12 (Hahn et al., 2005), appear to be on the
outs with respect to the main party of intertwined heli-
ces, consistent with evidence of prokaryotic relatives
lacking these domains altogether and the low degree
of sequence conservation in these two domains. Data
describing functional contributions to ligand binding in
mammalian TMs 11 and 12 may thus reflect indirect, al-
losteric perturbations of transport.
Another interesting residue in this region is a highly
conserved TM 1 Gly residue that shifts to an Asp in the
monoamine transporters (Barker et al., 1999). The
LeuTAa structure indicates that the b-carboxy group
of Asp may compensate for the absence of a carboxyl
group on 5-HT and collaboratively organize Na ion bind-
ing as a critical feature of coupled transport (Barker
et al., 1999). Moreover, the structural model of LeuTAa
predicts that leucine binding is stabilized by two distinct
hands within the binding pocket. One is this charged
network that includes Na itself, which interacts with
the charged carboxyl and amino moieties in the dehy-
drated leucine. The other hand is a hydrophobic binding
surface formed by the side chains of Val104, Tyr108,
Phe253, Ser256, Phe259, Ser355, and Ile359, encom-
passing residues from TMs 3, 6, and 8 that appear to
nestle the aliphatic methyl groups of the leucine side
chain. A common interaction site for substrate and Na
ions in TM 1 also reveals to us that both Na and organic
substrate pass through a common pore, an idea sup-
ported by electrophysiological experiments on Dro-
sophila SERT (dSERT) (Petersen and DeFelice, 1999).Na interaction within TM 1 was also suggested by muta-
genesis studies that link ion sensitivity to specific TM 1
residues of both SERT and GAT-1. For example, a con-
servative mutation in rSERT TM1, viz., Asp98Gln (LeuTAa
Gly24), results in diminished Na coupling (Barker et al.,
1999), similar to homologous mutations found by the
Kanner group in GAT-1, Gly63Ser/Cys (Gly 24). How
other aspects of substrate structure are discriminated
will soon, no doubt, come under attack by modeling
and site-directed mutagenesis.
SCAM analysis of hSERT TM 1 further suggested that
the conserved three amino acids Arg-Phe-Pro, located
at the top of the helix, are important for folding and
translocation to the plasma membrane (Henry et al.,
2003). Yamashita and colleagues (Yamashita et al.,
2005) propose that Arg40 in this domain forms a gate
that ion-pairs with Asp404 of TM 10. As mutation of
Arg104 in hSERT leads to loss of transporter protein sur-
face expression, it seems possible that this ionic inter-
action has a 2-fold function by first providing contacts
necessary for correct folding and later is employed in
the folded structure to support the proposed ‘‘hinged-
gate’’ for substrate access to the core binding residues.
Although the two proposed gating residues could form
a salt bridge, Asp404 is not conserved in Drosophila,
mosquito, or hornworm SERTs, which instead have
Asn in the homologous position in TM 10. Since the
charged pair in LeuTAa appears to interact via interspan-
ning water molecules, the oxygen of the Asn side chain
could compensate for the loss of the charged Glu. Ex-
periments within LeuTAa and homologs to interconvert
these charge pairs may reveal more about their func-
tional roles.
What does the structure tell us about where trans-
porter antagonists bind? In a SCAM analysis of hSERT
TM3, residues homologous to LeuTAa Val104 (Ile172)
and Tyr108 (Tyr176) were predicted to lie proximal to
substrate and inhibitor binding sites (Chen et al.,
1997). Recently, we substituted hSERT Ile172 with Met
(the homologous residue in dSERT) and observed a large
decrease in antidepressant potency (as much as 10003)
but remarkably no effect on substrate binding or trans-
port (Henry et al., 2006). Furthermore, a TM 1 (Tyr95Phe)
mutation combined with the Ile172Met substitution re-
sulted in a 10,000-fold loss of antagonist potency. This
Minireview
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bination with formation of high-affinity metal binding
sites through engineered cysteines in TMs 1 and 3 of
GAT-1 (Zomot et al., 2005) and hSERT (Henry et al.,
2006) strongly suggests cooperation of these two do-
mains in high-affinity antagonist recognition. In a prelim-
inary model of hSERT based on the LeuTAa structure, we
can see that indeed Y95 and I172M sit across from one
another in the substrate binding pocket (Figure 4). Sub-
stitution of Met for the Ile172 homologous residue in NET
and DAT preserves binding of substrates but results in
complete loss of transport (Henry et al., 2006) and other
hDAT substitutions at the residue analogous to hSERT
Ile172 reduced transport of the neurotoxin MPP+ (Lee
et al., 2000). Together, these findings indicate that
some, but not all, antagonists clearly make extensive
contacts within the substrate binding pocket and that
mutations in the region can collectively impact binding
of substrates and antagonists as well as modulate sub-
strate translocation.
Below the bound substrate, an intracellular gate is
formed in LeuTAa by TMs 1, 6, and 8, which converge
to form a more elaborate and extensive barrier when
compared to regions visualized as supporting the exter-
nal gate. The intracellular gate also contains a universally
conserved charge pair that forms a true salt bridge and
may act to preferentially stabilize an outward facing
transporter whose pore is occluded at the intracellular
face. Gouaux and colleagues suggest that unwound re-
gions within the TMs may provide flexibility and underlie
the mechanism for opening and closing of these gates.
The V-shape of TMs 4–5 and 9–10 nestle TM 3 and 8
Figure 4. Model of hSERT Substrate and Antagonist Binding Site
Helical model displayed is based on hSERT SCWRL3 model using
LeuTAa mainchain coordinates. Residues suggested to be involved
in substrate, ion, and antagonist binding are designated in ball-
and-stick model on TMs involved in substrate binding from LeuTAa
structure (other helices are not shown for clarity). Suggested binding
site is shown by semitransparent sphere.like pincers. If binding substrate and Na causes TM 1
and 6 as well as TM 3 and 8 to move, it is conceivable
that the ‘‘pincers’’ could effect conformational change
and coordinate opening and closing of the gates for
the permeation pathway (Sen et al., 2005). Imperfect co-
ordination has been suggested as a general means to
account for channels in transporters (Gadsby, 2004).
Further biochemical modeling and dynamic studies are
needed before we truly understand how substrate dock-
ing is translated into the swinging of these ‘‘gates.’’
Besides offering insight into substrate and ion bind-
ing, the packing of LeuTAa in the crystal lattice hints at
possible aspects of transporter oligomerization, which
features prominently in the function of channels and
transporters (DeFelice, 2004; Sitte et al., 2004). Although
LeuTAa arranges in dimers in the crystal, it is unclear
whether the exact dimer presented occurs naturally
(packing in an ordered fashion is necessary for crystalli-
zation, but in many cases such packing is simply what
packs well under the chosen conditions, not the true
multimeric structure) or even whether LeuTAa forms
higher-order assemblages as proposed for its eukary-
otic counterparts (Sitte et al., 2004). The dimer interface
of LeuTAa is formed by EL2, TMs 9 and 12 such that TMs
9 and 12 from each protomer form a four-helix bundle.
Recent data suggest that TMs 11 and 12 of the eukary-
otic NSS family members are involved in oligomerization
and that the transporter exists as a tetramer (Sitte et al.,
2004). Other data suggest that DAT TM 6 is involved in
dimerization, but in LeuTAa TM6 is buried in the core of
the transporter and unlikely to be involved in dimeriza-
tion (Sitte et al., 2004). However, in hDAT, residue
C306 in the loop between TMs 6 and 7 appears accessi-
ble in the LeuTAa model for intermolecular interactions
and could be involved in dimerization. Finally, a role for
TM2 in dimerization of mammalian transporters has
been proposed, based on conserved intramembrane
leucine heptad repeats. This motif is intact in GAT-1
but only partially conserved in DAT and SERT, and the
crystal structure of LeuTAa reveals that the portion of
TM 2, which contains the leucines in the incomplete mo-
tif, is buried and unlikely to act as a dimer interface. Un-
derstanding oligomerization domains and their impact
on intermolecular communication within the homomeric
complex could help us understand emerging data of
drug allosterism (Chen et al., 2005) and possibly also
the growing number of functional coding variants linked
to neurological/psychiatric disorders (Sutcliffe et al.,
2005).
One area of SLC6 transporter research that the struc-
ture of LeuTAa cannot address well is regulation medi-
ated by cytoplasmic domains (Sung et al., 2005). The cy-
toplasmic N and C termini in LeuTAa are quite short
compared to their mammalian counterparts. However,
the small N terminus in LeuTAa does insinuate at the
base of TMs 1 and 6, which organize part of the leucine
binding site, thus suggesting that the N-tail may affect
the flow of ions and/or organic substrates. Intriguing in
this regard is the mode of action of syntaxin-1A, a
plasma membrane SNARE protein whose cytoplasmic
domain binds the N terminus of multiple SLC6 family
members and in SERT has been shown to alter the rela-
tive flux stoichiometry of Na and 5-HT (Quick, 2003).
Since the N terminus leads directly to TM1, perhaps
Neuron
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face to enhance the fidelity of Na coupling.
Deriving mechanism from a transporter crystal struc-
ture is like reviewing a movie with only a single frame.
The solved LeuTAa structure contains bound substrates
with both presumed gates (extracellular and intracellu-
lar) closed. This was taken by Gouaux and coworkers
as support of the alternating access transport model,
where substrates enter through an extracellular aque-
ous pore to a centrally located binding site. The extra-
cellular gate closes, preventing back flow, then the intra-
cellular gate opens allowing the substrates to enter the
cytoplasm. The transporter returns empty to an outward
conformation allowing the next transport cycle to begin.
However, realistically, how much in the way of mecha-
nism may we ask of a single structure? It is unreasonable
to expect the cotransport machinery proposed by
Gouaux and colleagues to explain all of the existing
transport data, and many questions remain, though cer-
tainly much has been learned. Is it possible for example
that binding either the co-ion or substrate alone could
lead to gate closure and translocation? Is the ratcheting
turnstile ever partially open at both ends? Transport
from such states might be termed uncoupled and could
perhaps explain the evidence that suprastoichiometric
ion currents are known to pass through many SLC6
transporters, sometimes in the absence of organic sub-
strates (DeFelice and Blakely, 1996; Lester et al., 1996).
Clarifying this point should help explain the propensity
of some of the transporters in this family to masquerade
as ion channels. Or should we even care about the dis-
tinctions? There is evidence of single amino acid muta-
tions changing a channel into a transporter and vice
versa. A prototypical example of the channel/trans-
porter conundrum is the divalent metal transporter
DMT1. A point mutation in this transporter associated
with anemia converts DMT1 into a Ca2+ channel (Xu
et al., 2004). In line with this phenomenon, CLC-ec1,
which was thought to be a Cl2 channel, is actually
a counter-transporter (exchanger) that can be converted
into a Cl2 channel by a point mutation near the Cl2 bind-
ing site (Accardi and Miller, 2004). The switch of trans-
porters to channels and the ability of expression density
and interacting proteins to modulate flux stoichiometry
in SLC6 family members warn us against a premature
acceptance of the of LeuTAa snapshot as a complete
statement of the permeation mechanism. Certainly, the
LeuTAa crystal structure is the gateway to future travels,
but, of course, we have only just gotten to the subway
station, and complete mechanistic insight will require
a few more tokens, and maybe a train transfer or two.
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